Glycaemic control
Records checked
Compiled and citation-checked by GLP-1 Receptor Agonists editorial desk
Qualified clinical review None on record
Records whose assigned subject headings cover blood glucose, glycated haemoglobin, insulin handling or the diabetes populations indexed alongside them. 114 of the 186 records indexed across this publication's scope carry at least one of them, covering all 17 compounds.
Assignment is mechanical. A record sits under this endpoint because the indexer attached one of the subject headings listed further down, not because anyone read it. The cell counts records. It does not report a result, a direction or a magnitude, and nothing in the corpus would let it.
Record coverage by compound and record class
| Compound | Ph 3 | Ph 2 | Ph 1 | Trial, no phase | Review | Other | All |
|---|---|---|---|---|---|---|---|
| Amylin | 0 | 0 | 0 | 0 | 5 [80, 85, 94, 107, 113] | 4 [109, 110, 111, 114] | 9 |
| Cagrilintide | 5 [20, 25, 26, 27, 38] | 0 | 0 | 0 | 1 [18] | 1 [22] | 7 |
| Dulaglutide | 3 [44, 53, 60] | 0 | 0 | 8 [45, 50, 52, 54, 57, 63, 69, 70] | 0 | 1 [62] | 12 |
| Eloralintide | 0 | 0 | 0 | 0 | 1 [14] | 0 | 1 |
| Exenatide | 3 [73, 93, 100] | 0 | 0 | 2 [86, 98] | 0 | 4 [66, 84, 99, 101] | 9 |
| GLP-1 | 0 | 1 [77] | 0 | 0 | 5 [71, 72, 74, 102, 104] | 1 [97] | 7 |
| Liraglutide | 4 [51, 55, 59, 68] | 1 [75] | 0 | 1 [83] | 0 | 5 [56, 64, 67, 78, 79] | 11 |
| Lixisenatide | 1 [91] | 1 [89] | 0 | 4 [65, 88, 90, 92] | 0 | 4 [76, 81, 82, 95] | 10 |
| Maridebart cafraglutide | 0 | 1 [39] | 0 | 0 | 1 [1] | 1 [7] | 3 |
| Mazdutide | 3 [9, 10, 24] | 0 | 0 | 1 [5] | 4 [16, 17, 31, 43] | 1 [37] | 9 |
| Orforglipron | 4 [6, 15, 28, 30] | 0 | 1 [8] | 0 | 2 [11, 12] | 0 | 7 |
| Petrelintide | 0 | 0 | 0 | 0 | 1 [14] | 0 | 1 |
| Pramlintide | 0 | 0 | 0 | 3 [58, 87, 112] | 2 [105, 106] | 4 [61, 96, 103, 108] | 9 |
| Retatrutide | 1 [23] | 2 [40, 41] | 0 | 1 [2] | 0 | 2 [13, 32] | 6 |
| Semaglutide | 0 | 0 | 0 | 3 [36, 46, 47] | 0 | 2 [48, 49] | 5 |
| Survodutide | 2 [3, 4] | 2 [29, 35] | 0 | 2 [21, 33] | 2 [19, 42] | 0 | 8 |
| Tirzepatide | 2 [34, 44] | 0 | 0 | 1 [45] | 0 | 0 | 3 |
Column keys: Ph 3 phase 3; Ph 2 phase 2; Ph 1 phase 1; Trial, no phase trial, no phase assigned; Review review or synthesis; Other not a registered trial record. Phase is read from the publication type the indexer assigned to each record, never from its title.
A zero cell records that no indexed record for that compound carries one of these subject headings. It is the absence of a retrieved report, never the absence of the thing itself. The full record set for each compound is held on its own trial page.
Subject headings that place a record here
The full set is fixed and printed here so the assignment can be checked by hand against the method. 18 of the 18 headings in the set occur on at least one record in scope.
| Subject heading | Records |
|---|---|
| Diabetes Mellitus, Type 2 | 91 |
| Hypoglycemic Agents | 81 |
| Blood Glucose | 38 |
| Metformin | 18 |
| Insulin | 14 |
| Diabetes Mellitus, Type 1 | 7 |
| Hypoglycemia | 7 |
| Postprandial Period | 6 |
| Insulin Resistance | 4 |
| Islets of Langerhans | 4 |
| Diabetes Mellitus | 2 |
| Diabetes Mellitus, Experimental | 2 |
| Glycated Hemoglobin | 2 |
| Glycemic Control | 2 |
| Insulin-Secreting Cells | 2 |
| Prediabetic State | 2 |
| Glucose | 1 |
| Hyperglycemia | 1 |
The records
114 distinct records, newest first within each class. A record indexed under more than one compound is listed once and named under each.
Phase 3 — 27 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 3 | pmid:41187967 | 2026 | Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1) Diabetes, obesity & metabolism · Clinical Trial, Phase III, research-article | human trial | Survodutide | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Injections, Subcutaneous; Double-Blind Method |
| 4 | pmid:41216778 | 2026 | Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes Diabetes, obesity & metabolism · Clinical Trial, Phase III, research-article | human trial | Survodutide | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Receptors, Glucagon; Anti-Obesity Agents; Hypoglycemic Agents; Body Mass Index |
| 6 | pmid:41275875 | 2026 | Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial Lancet (London, England) · Clinical Trial, Phase III, Multicenter Study | human trial | Orforglipron | Humans; Diabetes Mellitus, Type 2; Obesity; Fluorine Compounds; Oxadiazoles; Hypoglycemic Agents; Body Mass Index; Treatment Outcome |
| 9 | pmid:41407859 | 2026 | Mazdutide versus placebo in Chinese adults with type 2 diabetes Nature · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Mazdutide | Humans; Diabetes Mellitus, Type 2; Weight Loss; Blood Glucose; Peptides; Receptors, Glucagon; Placebos; Hypoglycemic Agents |
| 10 | pmid:41407860 | 2026 | Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes Nature · Clinical Trial, Phase III, Comparative Study | human trial | Mazdutide | Humans; Diabetes Mellitus, Type 2; Body Weight; Peptides; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Adult |
| 15 | pmid:41765029 | 2026 | Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial Lancet (London, England) · Clinical Trial, Phase III, Comparative Study | human trial | Orforglipron | Humans; Diabetes Mellitus, Type 2; Fluorine Compounds; Oxadiazoles; Hypoglycemic Agents; Treatment Outcome; Administration, Oral; Drug Administration Schedule |
| 20 | pmid:42009015 | 2026 | Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial The lancet. Diabetes & endocrinology · Clinical Trial, Phase III, Multicenter Study | human trial | Cagrilintide | Humans; Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Treatment Outcome; Drug Therapy, Combination; Double-Blind Method; Adult |
| 23 | pmid:42250575 | 2026 | Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial Lancet (London, England) · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Retatrutide | Humans; Diabetes Mellitus, Type 2; Blood Glucose; Fatty Acids; Peptides; Hypoglycemic Agents; Treatment Outcome; Exercise |
| 24 | pmid:42251595 | 2026 | Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial JAMA · Clinical Trial, Phase III, Multicenter Study | human trial | Mazdutide | Humans; Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Diarrhea; Nausea; Vomiting |
| 25 | pmid:42251856 | 2026 | Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study Lancet (London, England) · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Cagrilintide | Humans; Diabetes Mellitus, Type 2; Insulin; Blood Glucose; Hypoglycemic Agents; Drug Therapy, Combination; Double-Blind Method; Aged |
| 26 | pmid:42251859 | 2026 | Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study The lancet. Diabetes & endocrinology · Clinical Trial, Phase III, Comparative Study | human trial | Cagrilintide | Humans; Diabetes Mellitus, Type 2; Blood Glucose; Drug Combinations; Hypoglycemic Agents; Double-Blind Method; Adult; Aged |
| 27 | pmid:42251860 | 2026 | Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study The lancet. Diabetes & endocrinology · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Cagrilintide | Humans; Diabetes Mellitus, Type 2; Blood Glucose; Hypoglycemic Agents; Treatment Outcome; Exercise; Drug Administration Schedule; Double-Blind Method |
| 28 | pmid:42259339 | 2026 | Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial Lancet (London, England) · Clinical Trial, Phase III, Comparative Study | human trial | Orforglipron | Humans; Diabetes Mellitus, Type 2; Fluorine Compounds; Metformin; Benzhydryl Compounds; Oxadiazoles; Glucosides; Blood Glucose |
| 30 | pmid:42338042 | 2026 | Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials Diabetes, obesity & metabolism · Clinical Trial, Phase III, research-article | human trial | Orforglipron | Liver; Humans; Diabetes Mellitus, Type 2; Obesity; Fluorine Compounds; Benzhydryl Compounds; Oxadiazoles; Alanine Transaminase |
| 34 | pmid:39536238 | 2025 | Tirzepatide for Obesity Treatment and Diabetes Prevention The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Tirzepatide | Humans; Gastrointestinal Diseases; Diabetes Mellitus, Type 2; Prediabetic State; Obesity; Disease Progression; Body Weight; Weight Loss |
| 38 | pmid:40544432 | 2025 | Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes The New England journal of medicine · Clinical Trial, Phase III, Multicenter Study | human trial | Cagrilintide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Obesity; Weight Loss; Blood Glucose; Drug Combinations; Body Mass Index |
| 44 | pmid:41406444 | 2025 | Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes The New England journal of medicine · Clinical Trial, Phase III, Equivalence Trial | human trial | Dulaglutide, Tirzepatide | Humans; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Blood Glucose; Recombinant Fusion Proteins; Treatment Outcome; Injections, Subcutaneous; Double-Blind Method |
| 51 | pmid:35015037 | 2022 | Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial JAMA · Clinical Trial, Phase III, research-article | human trial | Liraglutide | Humans; Diabetes Mellitus; Obesity; Body Weight; Weight Loss; Placebos; Hypoglycemic Agents; Treatment Outcome |
| 53 | pmid:35914543 | 2022 | Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial The lancet. Diabetes & endocrinology · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Dulaglutide | Humans; Diabetes Mellitus, Type 2; Body Weight; Gastric Inhibitory Polypeptide; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Double-Blind Method |
| 55 | pmid:31539622 | 2020 | Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) Diabetes & metabolism · Clinical Trial, Phase III, Comparative Study | human trial | Liraglutide | Humans; Diabetes Mellitus, Type 2; Metformin; Blood Glucose; Hypoglycemic Agents; Treatment Outcome; Drug Therapy, Combination; Administration, Oral |
| 59 | pmid:32233338 | 2020 | A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity The New England journal of medicine · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Liraglutide | Humans; Gastrointestinal Diseases; Blood Glucose; Body Mass Index; Combined Modality Therapy; Injections, Subcutaneous; Double-Blind Method; Adolescent |
| 60 | pmid:32333876 | 2020 | Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial The lancet. Diabetes & endocrinology · Clinical Trial, Phase III, Comparative Study | human trial | Dulaglutide | Humans; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Administration, Oral; Adult; Aged; Middle Aged |
| 68 | pmid:31186120 | 2019 | Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial Lancet (London, England) · Clinical Trial, Phase III, Comparative Study | human trial | Liraglutide | Humans; Diabetes Mellitus, Type 2; Body Weight; Metformin; Treatment Outcome; Administration, Oral; Injections, Subcutaneous; Double-Blind Method |
| 73 | pmid:29246950 | 2018 | Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial Diabetes care · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Exenatide | Venoms; Humans; Diabetes Mellitus, Type 2; Body Weight; Metformin; Blood Glucose; Peptides; Delayed-Action Preparations |
| 91 | pmid:27527848 | 2016 | Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial Diabetes care · Clinical Trial, Phase III, Multicenter Study | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Metformin; Blood Glucose; Peptides; Drug Combinations; Hypoglycemic Agents |
| 93 | pmid:27651331 | 2016 | Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial The lancet. Diabetes & endocrinology · Clinical Trial, Phase III, Comparative Study | human trial | Exenatide | Venoms; Humans; Diabetes Mellitus, Type 2; Metformin; Benzhydryl Compounds; Glucosides; Peptides; Hypoglycemic Agents |
| 100 | pmid:23698396 | 2013 | Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X) Diabetes care · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Exenatide | Humans; Diabetes Mellitus, Type 2; Metformin; Peptides; Hypoglycemic Agents; Treatment Outcome; Drug Administration Schedule; Adult |
Phase 2 — 8 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 29 | pmid:42331726 | 2026 | Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity Diabetes, obesity & metabolism · Clinical Trial, Phase II, research-article | human trial | Survodutide | Humans; Diabetes Mellitus, Type 2; Insulin Resistance; Obesity; Metformin; Glucagon; Blood Glucose; Peptide Fragments |
| 35 | pmid:39821928 | 2025 | Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist Diabetes, obesity & metabolism · Clinical Trial, Phase II, research-article | human trial | Survodutide | Humans; Obesity; Hypoglycemic Agents; Body Mass Index; Treatment Outcome; Double-Blind Method; Sex Factors; Adolescent |
| 39 | pmid:40549887 | 2025 | Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial The New England journal of medicine · Clinical Trial, Phase II, Multicenter Study | human trial | Maridebart cafraglutide | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Receptors, Gastrointestinal Hormone; Anti-Obesity Agents; Immunoconjugates; Body Mass Index |
| 40 | pmid:40609566 | 2025 | Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial The lancet. Diabetes & endocrinology · Clinical Trial, Phase II, Multicenter Study | human trial | Retatrutide | Humans; Diabetes Mellitus, Type 2; Fatty Acids; Peptides; Recombinant Fusion Proteins; Hypoglycemic Agents; Double-Blind Method; Body Composition |
| 41 | pmid:40726454 | 2025 | Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids Diabetes, obesity & metabolism · Clinical Trial, Phase II, research-article | human trial | Retatrutide | Humans; Diabetes Mellitus, Type 2; Gastric Inhibitory Polypeptide; Peptide Hormones; Fatty Acids; Triglycerides; Peptides; Receptors, Glucagon |
| 75 | pmid:30122305 | 2018 | Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial Lancet (London, England) · Clinical Trial, Phase II, Comparative Study | human trial | Liraglutide | Humans; Obesity; Weight Loss; Blood Glucose; Placebos; Hypoglycemic Agents; Body Mass Index; Treatment Outcome |
| 77 | pmid:30293770 | 2018 | Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Lancet (London, England) · Clinical Trial, Phase II, Multicenter Study | human trial | GLP-1 | Humans; Diabetes Mellitus, Type 2; Weight Loss; Gastric Inhibitory Polypeptide; Blood Glucose; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome |
| 89 | pmid:27284114 | 2016 | Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial Diabetes care · Clinical Trial, Phase II, Comparative Study | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Body Weight; Metformin; Blood Glucose; Peptides; Drug Combinations |
Phase 1 — 1 record
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 8 | pmid:41325139 | 2026 | A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes Journal of diabetes investigation · research-article, Clinical Trial, Phase I | human trial | Orforglipron | Humans; Diabetes Mellitus, Type 2; Fluorine Compounds; Oxadiazoles; Blood Glucose; Hypoglycemic Agents; Prognosis; Follow-Up Studies |
Trial, no phase assigned — 25 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 2 | pmid:41160422 | 2026 | Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · Clinical Trial Protocol, research-article | other | Retatrutide | Humans; Diabetes Mellitus, Type 2; Obesity; Fatty Acids; Peptides; Hypoglycemic Agents; Kidney Function Tests; Glomerular Filtration Rate |
| 5 | pmid:41260459 | 2026 | Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial Contemporary clinical trials · Clinical Trial Protocol | other | Mazdutide | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Metformin; Blood Glucose; Peptides; Hypoglycemic Agents |
| 21 | pmid:42219222 | 2026 | Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial Diabetes, obesity & metabolism · Clinical Trial Protocol, methods-article | other | Survodutide | Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Anti-Obesity Agents; Treatment Outcome; Double-Blind Method; Adult |
| 33 | pmid:39495965 | 2025 | Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2) Obesity (Silver Spring, Md.) · Clinical Trial Protocol, research-article | other | Survodutide | Humans; Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Glucagon; Hypoglycemic Agents; Body Mass Index |
| 36 | pmid:40162642 | 2025 | Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes The New England journal of medicine · Equivalence Trial, Multicenter Study | human trial | Semaglutide | Humans; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Administration, Oral; Follow-Up Studies; Double-Blind Method; Aged; Middle Aged |
| 45 | pmid:37758044 | 2024 | Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics American heart journal · Clinical Trial Protocol, Research Support, Non-U.S. Gov't | other | Dulaglutide, Tirzepatide | Humans; Cardiovascular Diseases; Myocardial Infarction; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Double-Blind Method |
| 46 | pmid:38587233 | 2024 | Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes The New England journal of medicine · Randomized Controlled Trial | human trial | Semaglutide | Humans; Diabetes Mellitus, Type 2; Obesity; Stroke Volume; Double-Blind Method; Glucagon-Like Peptides; Heart Failure; Glucagon-Like Peptide-1 Receptor Agonists |
| 47 | pmid:38785209 | 2024 | Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes The New England journal of medicine · Multicenter Study, Randomized Controlled Trial | human trial | Semaglutide | Humans; Diabetic Nephropathies; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Glomerular Filtration Rate; Injections, Subcutaneous; Double-Blind Method |
| 50 | pmid:37991022 | 2023 | Effects of dulaglutide on alcohol consumption during smoking cessation JCI insight · research-article, Randomized Controlled Trial | human trial | Dulaglutide | Humans; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Double-Blind Method; Alcohol Drinking; Smoking Cessation; Adult |
| 52 | pmid:35658022 | 2022 | Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes The New England journal of medicine · Randomized Controlled Trial | human trial | Dulaglutide | Humans; Diabetes Mellitus, Type 2; Metformin; Blood Glucose; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Injections, Subcutaneous |
| 54 | pmid:33397768 | 2021 | Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) Diabetes care · Equivalence Trial, Research Support, Non-U.S. Gov't | human trial | Dulaglutide | Humans; Diabetes Mellitus, Type 2; Metformin; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Drug Therapy, Combination; Double-Blind Method |
| 57 | pmid:31924562 | 2020 | The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial The lancet. Diabetes & endocrinology · Multicenter Study, Randomized Controlled Trial | human trial | Dulaglutide | Humans; Diabetic Angiopathies; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Prospective Studies; Double-Blind Method |
| 58 | pmid:31974099 | 2020 | A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial Diabetes care · Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Pramlintide | Humans; Diabetes Mellitus, Type 1; Insulin; Blood Glucose; Hypoglycemic Agents; Insulin Infusion Systems; Drug Therapy, Combination; Cross-Over Studies |
| 63 | pmid:32865597 | 2020 | Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial) Diabetologia · Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Dulaglutide | Liver; Humans; Diabetes Mellitus, Type 2; Alanine Transaminase; Aspartate Aminotransferases; Recombinant Fusion Proteins; Hypoglycemic Agents; Liver Function Tests |
| 65 | pmid:30623563 | 2019 | Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycaemia in healthy people and people with type 2 diabetes Diabetes, obesity & metabolism · Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Blood Glucose; Peptides; Placebos; Cross-Over Studies; Double-Blind Method; Blood Pressure |
| 69 | pmid:31189509 | 2019 | Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial Lancet (London, England) · Multicenter Study, Randomized Controlled Trial | human trial | Dulaglutide | Humans; Diabetic Nephropathies; Albuminuria; Diabetes Mellitus, Type 2; Creatinine; Recombinant Fusion Proteins; Hypoglycemic Agents; Glomerular Filtration Rate |
| 70 | pmid:31189511 | 2019 | Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet (London, England) · Multicenter Study, Randomized Controlled Trial | human trial | Dulaglutide | Humans; Cardiovascular Diseases; Myocardial Infarction; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Double-Blind Method; Aged |
| 83 | pmid:28854085 | 2017 | Liraglutide and Renal Outcomes in Type 2 Diabetes The New England journal of medicine · Comparative Study, Randomized Controlled Trial | human trial | Liraglutide | Humans; Diabetic Nephropathies; Kidney Failure, Chronic; Albuminuria; Diabetes Mellitus, Type 2; Creatinine; Hypoglycemic Agents; Glomerular Filtration Rate |
| 86 | pmid:27106272 | 2016 | Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy Diabetes, obesity & metabolism · Randomized Controlled Trial | human trial | Exenatide | Myocardium; Liver; Pancreas; Heart; Pericardium; Adipose Tissue; Venoms; Humans |
| 87 | pmid:27208332 | 2016 | Mitigating Meal-Related Glycemic Excursions in an Insulin-Sparing Manner During Closed-Loop Insulin Delivery: The Beneficial Effects of Adjunctive Pramlintide and Liraglutide Diabetes care · Clinical Trial, research-article | human trial | Pramlintide | Humans; Diabetes Mellitus, Type 1; Hyperglycemia; Insulin; Blood Glucose; Hypoglycemic Agents; Insulin Infusion Systems; Drug Therapy, Combination |
| 88 | pmid:27222510 | 2016 | Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial Diabetes care · Randomized Controlled Trial | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Body Weight; Metformin; Blood Glucose; Peptides; Hypoglycemic Agents |
| 90 | pmid:27311491 | 2016 | Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial Diabetes care · Randomized Controlled Trial | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Body Weight; Metformin; Blood Glucose; Peptides; Hypoglycemic Agents |
| 92 | pmid:27650977 | 2016 | Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial Diabetes care · Multicenter Study, Randomized Controlled Trial | human trial | Lixisenatide | Humans; Diabetes Mellitus, Type 2; Body Weight; Metformin; Insulin; Blood Glucose; Peptides; Drug Combinations |
| 98 | pmid:24879836 | 2014 | Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1) Diabetes care · Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Exenatide | Venoms; Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Metformin; Thiazolidinediones; Blood Glucose; Peptides |
| 112 | pmid:18753666 | 2008 | Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity Diabetes care · research-article, Randomized Controlled Trial | human trial | Pramlintide | Humans; Weight Loss; Amyloid; Placebos; Hypoglycemic Agents; Body Mass Index; Body Size; Follow-Up Studies |
Review or synthesis — 23 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 1 | pmid:41054801 | 2026 | Novel GLP-1-based Medications for Type 2 Diabetes and Obesity Endocrine reviews · Review | other | Maridebart cafraglutide | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucagon-Like Peptide-1 Receptor Agonists |
| 11 | pmid:41640110 | 2026 | Efficacy and Safety of Oral GLP-1 RA Orforglipron on Weight and Glycemic Control According to Diabetes Status: A Systematic Review and Meta-Analysis Diabetes technology & therapeutics · Meta-Analysis, Systematic Review | other | Orforglipron | Humans; Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Fluorine Compounds; Oxadiazoles; Blood Glucose |
| 12 | pmid:41683830 | 2026 | Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes International journal of molecular sciences · review-article, Review | other | Orforglipron | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Fluorine Compounds; Oxadiazoles; Hypoglycemic Agents; Administration, Oral |
| 14 | pmid:41747885 | 2026 | Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes Peptides · Review | other | Eloralintide, Petrelintide | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Hypoglycemic Agents; Glucagon-Like Peptides; Islet Amyloid Polypeptide; Receptors, Islet Amyloid Polypeptide |
| 16 | pmid:41804840 | 2026 | Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non-Diabetic Adults: A Meta-Analysis of Randomised Controlled Trials Diabetes, obesity & metabolism · Meta-Analysis, Review | other | Mazdutide | Humans; Obesity; Weight Loss; Peptides; Anti-Obesity Agents; Hypoglycemic Agents; Treatment Outcome; Adult |
| 17 | pmid:41820018 | 2026 | Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes Expert opinion on therapeutic patents · Review | other | Mazdutide | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Peptides; Receptors, Glucagon; Anti-Obesity Agents; Hypoglycemic Agents |
| 18 | pmid:41834765 | 2026 | Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression Diabetes, obesity & metabolism · Meta-Analysis, Comparative Study | other | Cagrilintide | Humans; Obesity; Weight Loss; Blood Glucose; Anti-Obesity Agents; Treatment Outcome; Glucagon-Like Peptides; Randomized Controlled Trials as Topic |
| 19 | pmid:41855048 | 2026 | A review of survodutide: a new dual acting agonist Minerva endocrinology · Review | other | Survodutide | Animals; Humans; Diabetes Mellitus, Type 2; Obesity; Somatostatin; Receptors, Glucagon; Hypoglycemic Agents; Glucagon-Like Peptide-1 Receptor Agonists |
| 31 | pmid:42410325 | 2026 | Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis Diabetes, obesity & metabolism · Meta-Analysis, Systematic Review | other | Mazdutide | Humans; Diabetes Mellitus, Type 2; Obesity; Body Weight; Weight Loss; Peptides; Receptors, Glucagon; Hypoglycemic Agents |
| 42 | pmid:40922121 | 2025 | Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis Diabetes, obesity & metabolism · Meta-Analysis, Systematic Review | other | Survodutide | Humans; Diabetes Mellitus, Type 2; Weight Loss; Blood Glucose; Hypoglycemic Agents; Treatment Outcome; Adult; Randomized Controlled Trials as Topic |
| 43 | pmid:41028652 | 2025 | Mazdutide: First Approval Drugs · Review | other | Mazdutide | Humans; Diabetes Mellitus, Type 2; Obesity; Peptides; Receptors, Glucagon; Anti-Obesity Agents; Hypoglycemic Agents; Drug Approval |
| 71 | pmid:31422062 | 2019 | Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials The lancet. Diabetes & endocrinology · Meta-Analysis, Research Support, Non-U.S. Gov't | other | GLP-1 | Humans; Diabetic Nephropathies; Diabetic Angiopathies; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Treatment Outcome; Randomized Controlled Trials as Topic; Glucagon-Like Peptide-1 Receptor Agonists |
| 72 | pmid:31767182 | 2019 | Glucagon-like peptide 1 (GLP-1) Molecular metabolism · Research Support, Non-U.S. Gov't, review-article | other | GLP-1 | Humans; Diabetes Mellitus, Type 2; Obesity; Gastric Inhibitory Polypeptide; Insulin; Glucose; Blood Glucose; Receptors, Glucagon |
| 74 | pmid:29617641 | 2018 | Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Cell metabolism · Research Support, Non-U.S. Gov't, Review | rodent | GLP-1 | Animals; Humans; Mice; Rats; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Obesity; Weight Gain |
| 80 | pmid:28269785 | 2017 | The Link between Type 2 Diabetes and Neurodegeneration: Roles for Amyloid-β, Amylin, and Tau Proteins Journal of Alzheimer's disease : JAD · Review | other | Amylin | Brain; Animals; Humans; Neurodegenerative Diseases; Diabetes Mellitus, Type 2; tau Proteins; Amyloid beta-Peptides; Islet Amyloid Polypeptide |
| 85 | pmid:26649319 | 2016 | Islet Amyloid Polypeptide: Structure, Function, and Pathophysiology Journal of diabetes research · research-article, Review | other | Amylin | Islets of Langerhans; Humans; Diabetes Mellitus, Type 2; Structure-Activity Relationship; Insulin-Secreting Cells; Islet Amyloid Polypeptide |
| 94 | pmid:26071095 | 2015 | Amylin: Pharmacology, Physiology, and Clinical Potential Pharmacological reviews · Research Support, Non-U.S. Gov't, Review | other | Amylin | Animals; Humans; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Weight Loss; Hypoglycemic Agents; Energy Metabolism; Islet Amyloid Polypeptide |
| 102 | pmid:22236411 | 2012 | Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials BMJ (Clinical research ed.) · Meta-Analysis, research-article | other | GLP-1 | Venoms; Humans; Diabetes Mellitus, Type 2; Obesity; Weight Loss; Peptides; Receptors, Glucagon; Anti-Obesity Agents |
| 104 | pmid:22945360 | 2012 | GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nature reviews. Endocrinology · Review | other | GLP-1 | Venoms; Animals; Humans; Diabetes Mellitus, Type 2; Blood Glucose; Peptides; Hypoglycemic Agents; Treatment Outcome |
| 105 | pmid:21199269 | 2011 | The effect of pramlintide acetate on glycemic control and weight in patients with type 2 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis Diabetes, obesity & metabolism · Meta-Analysis, Systematic Review | other | Pramlintide | Humans; Diabetes Mellitus, Type 2; Hypoglycemia; Obesity; Body Weight; Treatment Outcome; Incidence; Female |
| 106 | pmid:21564002 | 2011 | Pramlintide and the treatment of diabetes: a review of the data since its introduction Expert opinion on pharmacotherapy · Review | other | Pramlintide | Humans; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Drug Interactions; Islet Amyloid Polypeptide |
| 107 | pmid:21742788 | 2011 | Islet amyloid polypeptide, islet amyloid, and diabetes mellitus Physiological reviews · Research Support, Non-U.S. Gov't, Review | other | Amylin | Pancreas; Islets of Langerhans; Secretory Vesicles; Endoplasmic Reticulum; Animals; Humans; Diabetes Mellitus; Diabetes Mellitus, Type 1 |
| 113 | pmid:16815800 | 2006 | Pancreatic signals controlling food intake; insulin, glucagon and amylin Philosophical transactions of the Royal Society of London. Series B, Biological sciences · research-article, Review | other | Amylin | Pancreas; Animals; Body Weight; Amyloid; Glucagon; Insulin; Eating; Islet Amyloid Polypeptide |
Not a registered trial record — 30 records
| No. | Identifier | Year | Record | Model | Indexed under | Subject headings |
|---|---|---|---|---|---|---|
| 7 | pmid:41287212 | 2026 | A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice Diabetes, obesity & metabolism · Comparative Study, research-article | rodent | Maridebart cafraglutide | Liver; Adipose Tissue; Animals; Mice, Inbred C57BL; Mice; Insulin Resistance; Obesity; Body Weight |
| 13 | pmid:41741376 | 2026 | Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models Obesity (Silver Spring, Md.) · research-article | rodent | Retatrutide | Liver; Animals; Mice, Inbred C57BL; Mesocricetus; Mice; Mice, Obese; Fatty Liver; Insulin Resistance |
| 22 | pmid:42228334 | 2026 | Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide Clinical pharmacokinetics · research-article, Multicenter Study | human trial | Cagrilintide | Humans; Liver Diseases; Hypoglycemic Agents; Injections, Subcutaneous; Area Under Curve; Adult; Aged; Middle Aged |
| 32 | pmid:39212900 | 2025 | Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice Endocrine · Comparative Study | rodent | Retatrutide | Kidney; Animals; Mice, Inbred C57BL; Mice; Diabetic Nephropathies; Diabetes Mellitus, Experimental; Blood Glucose; Fatty Acids |
| 37 | pmid:40479843 | 2025 | Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis EBioMedicine · research-article | rodent | Mazdutide | Brain; Animals; Humans; Mice; Diabetes Mellitus, Type 2; Disease Models, Animal; Peptides; Receptors, Glucagon |
| 48 | pmid:38958939 | 2024 | Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide JAMA ophthalmology · research-article | other | Semaglutide | Humans; Optic Neuropathy, Ischemic; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Incidence; Risk Factors; Retrospective Studies; Aged |
| 49 | pmid:39222642 | 2024 | Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials Lancet (London, England) · Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't | human trial | Semaglutide | Humans; Diabetes Mellitus, Type 2; Obesity; Stroke Volume; Treatment Outcome; Hospitalization; Aged; Middle Aged |
| 56 | pmid:31747801 | 2020 | Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension Arteriosclerosis, thrombosis, and vascular biology · Research Support, Non-U.S. Gov't, research-article | rodent | Liraglutide | Cells, Cultured; Endothelial Cells; Animals; Mice, Inbred C57BL; Mice, Knockout; Mice; Hypertension; Disease Models, Animal |
| 61 | pmid:32393892 | 2020 | A co-formulation of supramolecularly stabilized insulin and pramlintide enhances mealtime glucagon suppression in diabetic pigs Nature biomedical engineering · Research Support, Non-U.S. Gov't, research-article | rodent | Pramlintide | Animals; Swine; Rats, Sprague-Dawley; Diabetes Mellitus, Experimental; Polyethylene Glycols; Imidazoles; Macrocyclic Compounds; Glucagon |
| 62 | pmid:32562683 | 2020 | Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial The Lancet. Neurology · Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Dulaglutide | Humans; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Treatment Outcome; Double-Blind Method; Adult; Aged |
| 64 | pmid:30341767 | 2019 | Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease Hepatology (Baltimore, Md.) · Comparative Study, Research Support, Non-U.S. Gov't | human trial | Liraglutide | Humans; Diabetes Mellitus, Type 2; Body Weight; Metformin; Blood Glucose; Hypoglycemic Agents; Prognosis; Treatment Outcome |
| 66 | pmid:30640362 | 2019 | Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial JAMA neurology · Research Support, Non-U.S. Gov't, research-article | human trial | Exenatide | Brain; Neurons; Humans; Parkinson Disease; Insulin; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Signal Transduction |
| 67 | pmid:31034184 | 2019 | Liraglutide in Children and Adolescents with Type 2 Diabetes The New England journal of medicine · Comparative Study, Research Support, Non-U.S. Gov't | human trial | Liraglutide | Humans; Gastrointestinal Diseases; Diabetes Mellitus, Type 2; Metformin; Insulin; Blood Glucose; Hypoglycemic Agents; Drug Therapy, Combination |
| 76 | pmid:30292589 | 2018 | Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial The lancet. Diabetes & endocrinology · Research Support, Non-U.S. Gov't | other | Lixisenatide | Humans; Kidney Diseases; Albuminuria; Diabetes Mellitus, Type 2; Peptides; Glomerular Filtration Rate; Treatment Outcome; Middle Aged |
| 78 | pmid:27790809 | 2017 | Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial European journal of heart failure · Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Liraglutide | Humans; Atrial Fibrillation; Tachycardia, Ventricular; Diabetes Mellitus, Type 2; Chronic Disease; Disease Progression; Natriuretic Peptide, Brain; Peptide Fragments |
| 79 | pmid:28237263 | 2017 | 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial Lancet (London, England) · Comparative Study, Research Support, Non-U.S. Gov't | human trial | Liraglutide | Humans; Diabetes Mellitus, Type 2; Prediabetic State; Obesity; Body Weight; Weight Loss; Blood Glucose; Placebos |
| 81 | pmid:28449402 | 2017 | Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial Diabetes, obesity & metabolism · Comparative Study, Research Support, Non-U.S. Gov't | human trial | Lixisenatide | Kidney; Humans; Diabetic Nephropathies; Diabetes Mellitus, Type 2; Insulin; Peptides; Hypoglycemic Agents; Glomerular Filtration Rate |
| 82 | pmid:28608285 | 2017 | The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype Diabetologia · Research Support, Non-U.S. Gov't | rodent | Lixisenatide | Macrophages; Animals; Mice; Diabetes Mellitus, Type 2; Insulin Resistance; Inflammation; Peptides; Atherosclerosis |
| 84 | pmid:28910237 | 2017 | Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes The New England journal of medicine · Comparative Study, research-article | human trial | Exenatide | Venoms; Humans; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Peptides; Hypoglycemic Agents; Injections, Subcutaneous; Drug Administration Schedule |
| 95 | pmid:26630143 | 2015 | Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome The New England journal of medicine · Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Lixisenatide | Humans; Cardiovascular Diseases; Angina, Unstable; Myocardial Infarction; Diabetes Mellitus, Type 2; Peptides; Hypoglycemic Agents; Treatment Failure |
| 96 | pmid:24169554 | 2014 | Activity of pramlintide, rat and human amylin but not Aβ1-42 at human amylin receptors Endocrinology · Research Support, Non-U.S. Gov't | rodent | Pramlintide | COS Cells; Animals; Humans; Rats; Calcitonin; Peptide Fragments; Receptors, Calcitonin; Hypoglycemic Agents |
| 97 | pmid:24467746 | 2014 | GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody Endocrinology · Journal Article | rodent | GLP-1 | Duodenum; Cell Line; Venoms; Animals; Mice, Inbred C57BL; Mice, Knockout; Haplorhini; Humans |
| 99 | pmid:23141817 | 2013 | Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study Lancet (London, England) · Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Exenatide | Venoms; Humans; Diabetes Mellitus, Type 2; Peptides; Hypoglycemic Agents; Treatment Outcome; Drug Administration Schedule; Middle Aged |
| 101 | pmid:23728174 | 2013 | Exenatide and the treatment of patients with Parkinson's disease The Journal of clinical investigation · Research Support, Non-U.S. Gov't, research-article | human trial | Exenatide | Venoms; Humans; Parkinson Disease; Disease Progression; Weight Loss; Constipation; Peptides; Antiparkinson Agents |
| 103 | pmid:22815298 | 2012 | Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes Diabetes care · Research Support, Non-U.S. Gov't, research-article | human trial | Pramlintide | Humans; Diabetes Mellitus, Type 1; Insulin; Blood Glucose; Hypoglycemic Agents; Pancreas, Artificial; Postprandial Period; Adolescent |
| 108 | pmid:20094043 | 2010 | Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial Obesity (Silver Spring, Md.) · Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Pramlintide | Humans; Obesity; Weight Loss; Phentermine; Cyclobutanes; Appetite Depressants; Hypoglycemic Agents; Drug Therapy, Combination |
| 109 | pmid:20707388 | 2010 | The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity Biochemistry · Comparative Study, Research Support, Non-U.S. Gov't | rodent | Amylin | Animals; Rats; Diabetes Mellitus, Type 2; Phenols; Thiazoles; Catechin; Flavonoids; Amyloid |
| 110 | pmid:19475663 | 2009 | Atomic structures of IAPP (amylin) fusions suggest a mechanism for fibrillation and the role of insulin in the process Protein science : a publication of the Protein Society · Research Support, Non-U.S. Gov't, research-article | other | Amylin | Humans; Diabetes Mellitus, Type 2; Amyloid; Insulin; Carrier Proteins; Recombinant Fusion Proteins; Crystallography, X-Ray; Binding Sites |
| 111 | pmid:18556473 | 2008 | Atomic structure of the cross-beta spine of islet amyloid polypeptide (amylin) Protein science : a publication of the Protein Society · Research Support, Non-U.S. Gov't, research-article | other | Amylin | Islets of Langerhans; Humans; Diabetes Mellitus, Type 2; Disulfides; Amyloid; Histidine; Carrier Proteins; Recombinant Fusion Proteins |
| 114 | pmid:16884500 | 2006 | The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells The FEBS journal · Journal Article | other | Amylin | Islets of Langerhans; Cell Line; Humans; Amyloid; Microscopy, Electron, Transmission; Circular Dichroism; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Amino Acid Sequence |
What this page does not say
- It does not say what any record found. Subject headings describe what a record is about, not what it concluded.
- It does not rank the compounds. The column order is fixed by record class and the row order is alphabetical, neither of which carries a judgement.
- It does not represent the literature. The counts are of records this corpus carries; the queries behind them returned 48,938 records in total across the compounds in scope.
- It is not clinical guidance, and it is not reviewed by a clinician. The disclaimer states the limits in full.